Holen Sie sich die Stockscreener-App
9.2961
2.31%
0.2061
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
4DMT management to present at BofA, RBC healthcare conferences - Stock Titan
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Board moves key votes at 4D Molecular Therapeutics (NASDAQ: FDMT) 2026 meeting - Stock Titan
4D (FDMT) Stock Beneficial Ownership (Grinds Lower) 2026-04-20Real Time Stock Idea Network - Cổng thông tin điện tử tỉnh Lào Cai
4DMT Announces New Employment Inducement Grants - GlobeNewswire
Layoff Watch: What is the Moat Score of 4D Molecular Therapeutics Inc2026 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Janus Henderson (NASDAQ: FDMT) holds 5.25M shares, 10.3% stake in 4D Molecular - Stock Titan
Investment Analysts’ Recent Ratings Changes for 4D Molecular Therapeutics (FDMT) - Defense World
JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT - MarketBeat
Will 4D (FDMT) Stock Hit Record Highs | Price at $9.48, Down 3.95%Crowd Trend Signals - Newser
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A. - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Receives Buy Rating from Jefferies Financial Group - Defense World
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart - Capital.com
4D Molecular Therapeutics Consolidates Financial Leadership Under New Role - TipRanks
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Trade 4D Molecular Therapeutics IncFDMT CFD - Capital.com
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer - Stock Titan
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $32.71 Consensus Target Price from Analysts - Defense World
4D Molecular Therapeutics Inc : Jefferies Ass - Moomoo
CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options - Stock Titan
4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO - stocktitan.net
4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT) - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% HigherHere's Why - MarketBeat
VP Gupta of 4d molecular sold $3357 in FDMT stock - Investing.com UK
4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes - Stock Titan
Research Analysts Issue Forecasts for FDMT FY2030 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to "Hold" at Wall Street Zen - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Raised to “Hold” at Wall Street Zen - Defense World
4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald - The Globe and Mail
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at Chardan Capital - Defense World
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies - TipRanks
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada - MarketBeat
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus
Chardan Capital Reiterates "Buy" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. (FDMT) Q4 earnings and revenues beat estimates - MSN
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings Results, Beats Estimates By $0.96 EPS - MarketBeat
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):